Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BRC OA

Next Previous
Search
Drug Profile

BRC OA

Alternative Names: BRC-OA; Cryopreserved devitalized adipose tissue allograft - Britecyte

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Britecyte
  • Class Antirheumatics
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Osteoarthritis

Most Recent Events

  • 20 Feb 2025 Britecyte receives a “safe to proceed” status by the US FDA for its adipose tissue allograft (BRC-OA)
  • 20 Feb 2025 Britecyte has patent pending for BRC-OA (Britecyte Pipeline, February 2025)
  • 20 Feb 2025 The US FDA approves IND application for BRC-OA in Osteoarthritis prior to February 2025 (Britecyte Pipeline, February 2025)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top